Does apolipoprotein E (Apo-E) genotype influence nicotinic receptor binding in Alzheimer's disease

Journal of Neurology

Volumn 248, Issue 9, 2001, Pages 1043-1050

  Reid, R T ^a   Sabbagh, M N ^b   Thal, L J ^c  

^a Banck Clinical Research Center   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Apolipoprotein E; Choline acetyltransferase; Nicotinic receptors; Synaptophysin

Indexed keywords

APOLIPOPROTEIN E; EPIBATIDINE; NICOTINIC RECEPTOR; ACETYLCHOLINE; APOLIPOPROTEIN E4; CHOLINE ACETYLTRANSFERASE;

AGE DISTRIBUTION; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE LOSS; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; RECEPTOR BINDING; FRONTAL LOBE; GENE DOSAGE; GENE FREQUENCY; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; SYNAPSE;

ACETYLCHOLINE; AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CHOLINE O-ACETYLTRANSFERASE; FRONTAL LOBE; GENE DOSAGE; GENE FREQUENCY; GENOTYPE; HUMANS; NEURONS; RECEPTORS, NICOTINIC; SYNAPSES;

EID: 0034876250     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. A simple dot-immunobinding assay for quantification of synaptophysin-like immunoreactivity in human brain
2. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases
3. Apolipoprotein E, plaques, tangles, and cholinergic function dysfunction in Alzheimer's disease
4. Apolipoprotein E allele epsilon 4 is linked to increased deposition of the amyloidβ-peptide (Aβ) in cases with or without Alheimer's disease
5. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
6. E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer's disease
7. Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease
8. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer disease
9. 3H]Nicotine binding in human cerebral cortex: Comparison between Alzheimer's disease and the normal
10. Radiochemical microassay for the determination of choline acetyltransferase and acetylcholinesterase activities
11. Regional variation in the distribution of apolipoprotein E and Aβ in Alzheimer's disease
12. Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer's disease
13. Alzheimer pathology of patients carrying apolipoprotein E epsilon 4 allele
14. 3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain
15. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein MAP2c: Implications for Alzheimer's disease
16. Diagnosis of Alzheimer's disease
17. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop
18. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
19. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part II. Standardization of the neuropathologic assessment of Alzheimer's disease
20. Molecular biology of Apo E alleles in Alzheimer's and non Alzheimer's dementias
21. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease
22. 3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains
23. Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia
24. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation
25. Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions
26. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson, and Lewy body types
27. Alteration in nicotinic binding sites in Parkinson's disease, Lewy body dementia, and Alzheimer's disease: Possible index of early neuropathology
28. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease
29. Apolipoprotein E4 allele as a predictor of cholingeric deficits and treatment outcome in Alzheimer's disease
30. Nicotinic receptor in dementia with Lewy Bodies: Comparisons with Alzheimer's disease
31. Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: Implications for disease pathogenesis
32. A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease
33. ApoE is a major susceptibility gene for Alzheimer's disease
34. Correlation of nicotinic binding to neurochemical markers in Alzheimer's disease
35. Association of apolipoprotein E allele ε4 with late onset and sporadic Alzheimer's disease
36. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease
37. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation
38. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: Implications for Alzheimer disease
39. Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzhiemer patient with differing apolipoprotein genotypes
40. Some morphometric aspects of the brain in senile dementia of the Alzheimer type
41. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment
42. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains
43. Apolipoprotein E genotyping by one-stage PCR